Jeffrey A Gelfand

This inventor holds 20 USPTO granted patents and 19 published patent applications and 3 EPO patents, primarily in Cancer Immunotherapy. Top assignees: The General Hospital Corporation, Suspension Orthopaedic Solutions, Inc., Aperisys, Inc.. Active years: 1993-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey A Gelfand. Retrieved from https://idiyas.com/inventor/jeffrey-a-gelfand

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 19)

% Patents Active = 95.0

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 1.7

ph-index = 7

Forward Citations = 157(Granted Patents)

Location History:

Severna Park, MD (US) (2012 - 2015)
Boston, MA (US) (2013 - 2021)
Cambridge, MA (US) (1993 - 2023)

Company Filing History:

14 out of 3,079

The General Hospital Corporation

patents

3 out of 3

Suspension Orthopaedic Solutions, Inc.

New England Medical Center Hospitals. Inc.

where one patent can have more than one assignee

Years Active: 1993-2026

Loading Chart...

Areas of Expertise:

HSP Fusion Proteins

Cancer Treatment

Antigen-Binding Proteins

Immunotherapy

Viral Infections

Photodynamic Therapy

Self-Assembling Vaccines

Mesothelin Antibody Fusions

Infectious Disease

Medical Screening

Protein Engineering

Activated T Cells

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12540165 - HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer (2026-02-03),

2. 11718683 - Antigen-binding fusion proteins with modified HSP70 domains (2023-08-08),

3. 11547694 - CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease (2023-01-10),

4. 11453706 - HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease (2022-09-27),

5. 11364264 - Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer (2022-06-21),

6. 11325951 - HSP fusion protein with anti-chemorepellant agent for treatment of cancer (2022-05-10),

7. 11135445 - Antimicrobial photodynamic inactivation procedure and system (2021-10-05),

8. 11135220 - Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione (2021-10-05),

9. 10800837 - Immunotherapies employing self-assembling vaccines (2020-10-13),

10. 10780294 - System and method for photo-dynamic procedure (2020-09-22),

11. 9527906 - Immunotherapies employing self-assembling vaccines (2016-12-27),

12. 9149312 - Clavicle fixation (2015-10-06),

13. 8439918 - Ulna fixation (2013-05-14),

14. 8435494 - Mesothelin antibody protein fusions and methods of use (2013-05-07),

15. 8282674 - Clavicle fixation (2012-10-09),

Title: Innovations and Contributions of Jeffrey A. Gelfand

Introduction

Jeffrey A. Gelfand is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of biotechnology. With a total of 16 patents to his name, Gelfand has made remarkable advancements in the development of therapeutic proteins and treatments for various diseases.

Latest Patents

Among his latest patents, Gelfand has developed antigen-binding fusion proteins with modified HSP70 domains. This invention relates to fusion proteins that comprise an antigen binding domain fused with a modified heat shock 70 protein. The invention further includes methods of using these fusion proteins to induce an immune response to antigens and to treat diseases associated with those antigens. Another notable patent involves the blockade of CXCR4/CXCR7 for the treatment of human papilloma virus-associated diseases. This invention outlines methods and compositions for treating HPV-associated diseases using an inhibitor of CXCL12 signaling. It also includes methods for treating immune checkpoint blockade resistant diseases and enhancing the immune response against HPV-associated diseases.

Career Highlights

Gelfand has worked with notable organizations such as The General Hospital Corporation and Boston Biocom LLC. His work in these institutions has allowed him to further his research and develop innovative solutions in the medical field.

Collaborations

Some of his notable coworkers include Mark C. Poznansky and Timothy Alan Brauns. Their collaborative efforts have contributed to the advancement of Gelfand's research and inventions.

Conclusion

Jeffrey A. Gelfand's innovative work in biotechnology and his numerous patents highlight his significant impact on medical research and treatment methodologies. His contributions continue to pave the way for advancements in healthcare and therapeutic solutions.

Profile summary based on public USPTO records.